Molecular targets and the treatment of myeloid leukemia

Molecular Genetics and Metabolism

Volumn 88, Issue 3, 2006, Pages 216-224

  Ikeda, A ^a   Shankar, D B ^a   Watanabe, M ^c   Tamanoi, F ^c   Moore, T B ^a   Sakamoto, K M ^a,b,c,d  

^a Gwynne Hazen Cherry Memorial Laboratories   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Apoptosis; Cell cycle; Chromosomal translocations; Small molecule inhibitors; Targeted therapy

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; ALPHA INTERFERON; AMIDE; ARSENIC TRIOXIDE; BCR ABL PROTEIN; BUTYRIC ACID; CEP 701; CORE BINDING FACTOR; CYTARABINE; DASATINIB; FLT3 LIGAND; HISTONE DEACETYLASE INHIBITOR; IMATINIB; KI 23819; L 778123; LONAFARNIB; MIDOSTAURIN; NILOTINIB; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; RAS PROTEIN; RECEPTOR BLOCKING AGENT; RETINOIC ACID; SEMAXANIB; SUNITINIB; TIPIFARNIB; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME ABERRATION; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; CYTOGENETICS; DRUG TARGETING; FUSION GENE; GENE MUTATION; HUMAN; MOLECULAR BIOLOGY; MYELOID LEUKEMIA; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; HUMANS; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, PROMYELOCYTIC, ACUTE; PIPERAZINES; PYRIMIDINES; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC; TRETINOIN;

EID: 33745547147     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2006.03.011     Document Type: Review

References (94)

1. Stone R.M., O'Donnell M.R., and Sekeres M.A. Acute myeloid leukemia. Hematology (Am. Soc. Hematol. Educ. Program) (2004) 98-117
2. Vogelstein B., and Kinzler K.W. The multistep nature of cancer. Trends Genet. 9 4 (1993) 138-141
3. Shankar D.B., et al. The Role of CREB as a Proto-Oncogene in Hematopoiesis and in Acute Myeloid Leukemia. Cancer Cell (2005) 7
4. Bartek J., and Lukas J. Are all cancer genes equal?. Nature 411 6841 (2001) 1001-1002
5. Kelly L.M., and Gilliland D.G. Genetics of myeloid leukemias. Annu. Rev. Genomics Hum. Genet. 3 (2002) 179-198
6. Druker B.J., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344 14 (2001) 1038-1042
7. Druker B.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344 14 (2001) 1031-1037
8. Fenaux P., Chomienne C., and Degos L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin. Hematol. 38 1 (2001) 13-25
9. Van Etten R.A., and Shannon K.M. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 6 6 (2004) 547-552
10. John A.M., et al. Targeted therapies in myeloid leukemia. Semin. Cancer Biol. 14 1 (2004) 41-62
11. Chen Z., et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t (11;17) translocation associated with acute promyelocytic leukaemia. Embo J. 12 3 (1993) 1161-1167
12. Parmar S., and Tallman M.S. Acute promyelocytic leukaemia: a review. Expert Opin. Pharmacother. 4 8 (2003) 1379-1392
13. Tallman M.S., et al. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 99 3 (2002) 759-767
14. Brown D., et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 94 6 (1997) 2551-2556
15. Douer D., and Tallman M.S. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J. Clin. Oncol. 23 10 (2005) 2396-2410
16. Yergeau D.A., et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat. Genet. 15 3 (1997) 303-306
17. Castilla L.H., et al. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell 87 4 (1996) 687-696
18. Friedman A.D. Leukemogenesis by CBF oncoproteins. Leukemia 13 12 (1999) 1932-1942
19. Nucifora G., and Rowley J.D. The AML1 and ETO genes in acute myeloid leukemia with a t(8;21). Leuk. Lymphoma 14 5-6 (1994) 353-362
20. Melnick A., et al. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. Mol. Cell Biol. 22 6 (2002) 1804-1818
21. Durst K.L., et al. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain. Mol. Cell Biol. 23 2 (2003) 607-619
22. Wang J., et al. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res. 59 12 (1999) 2766-2769
23. Sawyers C.L. The bcr-abl gene in chronic myelogenous leukaemia. Cancer Surv. 15 (1992) 37-51
24. Ben-Neriah Y., et al. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233 4760 (1986) 212-214
25. Daley G.Q., Van Etten R.A., and Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247 4944 (1990) 824-830
26. Bedi A., et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 86 3 (1995) 1148-1158
27. Bedi A., et al. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83 8 (1994) 2038-2044
28. Sanchez-Garcia I., and Grutz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc. Natl. Acad. Sci. USA 92 12 (1995) 5287-5291
29. Sawyers C.L., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99 10 (2002) 3530-3539
30. Shah N.P., and Sawyers C.L. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22 47 (2003) 7389-7395
31. Sawyers C.L. Research on resistance to cancer drug Gleevec. Science 294 5548 (2001) 1834
32. Gorre M.E., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 5531 (2001) 876-880
33. Shah N.P., et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 5682 (2004) 399-401
34. O'Hare T., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65 11 (2005) 4500-4505
35. Weisberg E., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 2 (2005) 129-141
36. O'Hare T., Corbin A.S., and Druker B.J. Targeted CML therapy: controlling drug resistance, seeking cure. Curr. Opin. Genet. Dev. 16 1 (2006) 92-99
37. Krause D.S., and Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353 2 (2005) 172-187
38. Thiede C., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99 12 (2002) 4326-4335
39. Grundler R., et al. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood 105 12 (2005) 4792-4799
40. Yamamoto Y., et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97 8 (2001) 2434-2439
41. Weisberg E., et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1 5 (2002) 433-443
42. George D.J., et al. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res. 59 10 (1999) 2395-2401
43. O'Farrell A.M., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 9 (2003) 3597-3605
44. Yee K.W., et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood 100 8 (2002) 2941-2949
45. O'Farrell A.M., et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res. 9 15 (2003) 5465-5476
46. Heinrich M.C., et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 20 6 (2002) 1692-1703
47. Padua R.A., et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia 12 6 (1998) 887-892
48. Lowy D.R., and Willumsen B.M. Function and regulation of ras. Annu. Rev. Biochem. 62 (1993) 851-891
49. Morgan M.A., Ganser A., and Reuter C.W. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia. Leukemia 17 8 (2003) 1482-1498
50. Lancet J.E., and Karp J.E. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 102 12 (2003) 3880-3889
51. Cortes J. Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Clin. Lymphoma 4 Suppl 1 (2003) S30-S35
52. Karp J.E., et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 97 11 (2001) 3361-3369
53. Kurzrock R., et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood 102 13 (2003) 4527-4534
54. Kurzrock R., et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J. Clin. Oncol. 22 7 (2004) 1287-1292
55. Cortes J., et al. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J. Clin. Oncol. 23 12 (2005) 2805-2812
56. Alsina M., et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 103 9 (2004) 3271-3277
57. Efuet E.T., and Keyomarsi K. Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome. Cancer Res. 66 2 (2006) 1040-1051
58. Greenberg P.L. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk. Res. 22 12 (1998) 1123-1136
59. Chao D.T., and Korsmeyer S.J. BCL-2 family: regulators of cell death. Annu. Rev. Immunol. 16 (1998) 395-419
60. Traver D., et al. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 9 1 (1998) 47-57
61. Kogan S.C., et al. BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia. J. Exp. Med. 193 4 (2001) 531-543
62. Reed J.C. Apoptosis-targeted therapies for cancer. Cancer Cell 3 1 (2003) 17-22
63. List A., et al. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia 17 8 (2003) 1499-1507
64. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 6810 (2000) 307-310
65. Fang B., and Roth J.A. Tumor-suppressing gene therapy. Cancer Biol. Ther. 2 4 Suppl 1 (2003) S115-S121
66. Pines J. Cyclins and cyclin-dependent kinases: a biochemical view. Biochem. J. 308 Pt 3 (1995) 697-711
67. Hall M., Bates S., and Peters G. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11 8 (1995) 1581-1588
68. Friend S.H., et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323 6089 (1986) 643-646
69. Jamal R., et al. The retinoblastoma gene (rb1) in acute myeloid leukaemia: analysis of gene rearrangements, protein expression and comparison of disease outcome. Br. J. Haematol. 94 2 (1996) 342-351
70. Sauerbrey A., et al. Expression of the retinoblastoma tumor suppressor gene (RB-1) in acute leukemia. Leuk. Lymphoma 28 3-4 (1998) 275-283
71. Donnellan R., and Chetty R. Cyclin E in human cancers. FASEB J. 13 8 (1999) 773-780
72. Spruck C.H., Won K.A., and Reed S.I. Deregulated cyclin E induces chromosome instability. Nature 401 6750 (1999) 297-300
73. Solvason N., et al. Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. Int. Immunol. 12 5 (2000) 631-638
74. Iida H., et al. Overexpression of cyclin E in acute myelogenous leukemia. Blood 90 9 (1997) 3707-3713
75. Matushansky I., Radparvar F., and Skoultchi A.I. Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G1. Proc. Natl. Acad. Sci. USA 97 26 (2000) 14317-14322
76. Hoessel R., et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1 1 (1999) 60-67
77. Senderowicz A.M. The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist 7 Suppl 3 (2002) 12-19
78. Senderowicz A.M. Cyclin-dependent kinases as new targets for the prevention and treatment of cancer. Hematol. Oncol. Clin. North Am. 16 5 (2002) 1229-1253
79. Nucifora G., and Rowley J.D. The AML1 gene in the 8;21 and 3;21 translocations in chronic and acute myeloid leukemia. Cold Spring Harb. Symp. Quant. Biol. 59 (1994) 595-605
80. Gamou T., et al. The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family. Blood 91 11 (1998) 4028-4037
81. Dissing M., Le Beau M.M., and Pedersen-Bjergaard J. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?. J. Clin. Oncol. 16 5 (1998) 1890-1896
82. Shimada H., et al. Generation of the NUP98-HOXD13 fusion transcript by a rare translocation, t (2;11)(q31;p15), in a case of infant leukaemia. Br. J. Haematol. 110 1 (2000) 210-213
83. Hatano Y., et al. Molecular heterogeneity of the NUP98/HOXA9 fusion transcript in myelodysplastic syndromes associated with t (7;11)(p15;p15). Br. J. Haematol. 107 3 (1999) 600-604
84. Peeters P., et al. Fusion of ETV6 to MDS1/EVI1 as a result of t (3;12)(q26;p13) in myeloproliferative disorders. Cancer Res. 57 4 (1997) 564-569
85. Golub T.R. TEL gene rearrangements in myeloid malignancy. Hematol. Oncol. Clin. North Am. 11 6 (1997) 1207-1220
86. de The H., et al. The t (15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 347 6293 (1990) 558-561
87. Redner R.L., et al. The t (5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 87 3 (1996) 882-886
88. Arnould C., et al. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum. Mol. Genet. 8 9 (1999) 1741-1749
89. Blutters-Sawatzki R., et al. Secondary acute myeloid leukemia with translocation (4;11) and MLL/AF4 rearrangement in a 15-year-old boy treated for common acute lymphoblastic leukemia 11 years earlier. Ann. Hematol. 70 1 (1995) 31-35
90. Atlas M., et al. Cloning and sequence analysis of four t (9;11) therapy-related leukemia breakpoints. Leukemia 12 12 (1998) 1895-1902
91. Rowley J.D., et al. All patients with the t (11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 90 2 (1997) 535-541
92. Ahuja H.G., Felix C.A., and Aplan P.D. The t (11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOP1 fusion. Blood 94 9 (1999) 3258-3261
93. Nakao K., et al. Fusion of the nucleoporin gene, NUP98, and the putative RNA helicase gene, DDX10, by inversion 11 (p15q22) chromosome translocation in a patient with etoposide-related myelodysplastic syndrome. Intern. Med. 39 5 (2000) 412-415
94. Borrow J., et al. The translocation t (8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat. Genet. 14 1 (1996) 33-41